{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:56:20Z","timestamp":1761929780119},"reference-count":72,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adoptive cell therapy (<jats:styled-content style=\"fixed-case\">ACT<\/jats:styled-content>) for cancer represents a promising new treatment modality. <jats:styled-content style=\"fixed-case\">ACT<\/jats:styled-content> based on the administration of cytotoxic T cells genetically engineered to express a chimeric antigen receptor (<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>) recognizing <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19 expressed by B cell malignancies has been shown to induce complete lasting responses in patients with chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>) and acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). So far, eleven clinical trials including 99 <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> patients treated with <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T cells targeting <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19 have been published, and the results from these trials are promising with impressive clinical responses in heavily pretreated patients. Thus, <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T cell therapy has induced complete responses in both <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>, and surprisingly, current results indicate that patients with <jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content> are more prone to respond than are <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients. Importantly, the majority of <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> cell studies have observed severe therapy\u2010associated toxicities, which needs attention. Herein we review current data and discuss key aspects of this powerful approach to treat and potentially cure B cell malignancies.<\/jats:p>","DOI":"10.1111\/sji.12331","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T03:54:58Z","timestamp":1435031698000},"page":"307-319","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["<scp>CD<\/scp>19\u2010Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia"],"prefix":"10.1111","volume":"82","author":[{"given":"C. L.","family":"Lorentzen","sequence":"first","affiliation":[{"name":"University of Copenhagen Copenhagen Denmark"},{"name":"Center for Cancer Immune Therapy (CCIT) Department of Hematology 65Q9 Copenhagen University Hospital Herlev Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. T.","family":"Straten","sequence":"additional","affiliation":[{"name":"Center for Cancer Immune Therapy (CCIT) Department of Hematology 65Q9 Copenhagen University Hospital Herlev Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-492231"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21235"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.348"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12126"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc971"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4650"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90314-O"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0674"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm827"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6123"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0160"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.122"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.46"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25960"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1676"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation.V2012.1.143.3798224","article-title":"Novel cellular therapies for leukemia: CAR\u2010modified T cells targeted to the CD19 antigen","volume":"2012","author":"Brentjens RJ","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.75"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000040"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128843"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1479-5"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ac6138"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.215"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.06.003"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.10.013"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318194a6e8"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2012.12.004"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2010.542461"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.070"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.075"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300404"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.05.022"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.179"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064138"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-242263"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-366419"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4112"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.189"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20643"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000031"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_12_61_1","first-page":"1509","article-title":"Chimeric antigen receptor\u2010modified T cells for acute lymphoid leukemia. N.Engl","volume":"368","author":"Grupp SA","year":"2013","journal-title":"J Med"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.01.003"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225326"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22524"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1490-x"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.e317"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.715350"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061338"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2013.34"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-376137"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829903"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fsji.12331","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/sji.12331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:17:49Z","timestamp":1696184269000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/sji.12331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/sji.12331"],"URL":"https:\/\/doi.org\/10.1111\/sji.12331","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,10]]},"assertion":[{"value":"2015-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}